IMMP Faces Securities Investigation After 80-90% Collapse Tied to Halted TACTI-004 Trial
Immutep Investors Grapple with Historic Losses Amid Class Action Investigation
Immutep Ltd. (NASDAQ: IMMP) is under intense scrutiny after its shares suffered an unprecedented decline—shedding as much as 80% to 90% of their value—following the sudden halt of its flagship Phase III oncology trial. Levi & Korsinsky, a law firm with a track record in complex securities litigation, has announced an investigation into whether Immutep adequately disclosed the material risks related to the trial’s viability prior to this dramatic event.
Background: TACTI-004 Trial Halt Sparks Legal Action
The primary catalyst was the Independent Data Monitoring Committee’s (IDMC) recommendation to discontinue the TACTI-004 (KEYNOTE-F91) trial, Immutep’s lead clinical-stage program targeting first-line non-small-cell lung cancer. The halt came after an interim futility analysis indicated the trial was unlikely to succeed in meeting efficacy endpoints. Despite earlier statements in a January 2026 filing touting “strong operational progress,” the March 13, 2026 announcement caught many off guard, culminating in an 80-90% stock drop in a single day.
Key Press Release Facts
| Event | Date | Details |
|---|---|---|
| TACTI-004 Futility Analysis | Q1 2026 | Analysis determined trial unlikely to meet efficacy endpoints |
| Public Disclosure of Trial Halt | March 13, 2026 | IDMC recommended study stop, causing 80-90% share price collapse |
| Securities Investigation Announcement | April 15, 2026 | Levi & Korsinsky investigates possible failure to disclose risks |
Legal Probe Focuses on Potential Gaps in Disclosure
The central issue prompting the investigation is whether Immutep’s public disclosures misrepresented or omitted critical updates about the trial’s status, thereby exposing shareholders to unexpected risk. Significant attention is being paid to the company’s statements in late January 2026, when it communicated positive progress even as the crucial futility analysis approached.
Current Stock Snapshot: Stability Remains Uncertain
As of 11:12 AM, IMMP traded at $0.61 per share, reflecting a 12.13% intraday gain. Still, this modest uptick does little to offset the catastrophic loss endured by investors since the March collapse:
| Price | Change | Percent Change |
|---|---|---|
| $0.61 | +$0.07 | +12.13% |
Shareholders Invited to Participate in Class Action Inquiry
Levi & Korsinsky’s investigation provides an avenue for investors with losses to potentially seek compensation if securities laws were violated. The firm, recognized for its results in shareholder litigation, encourages those affected to submit their information before the review concludes. Contact details for the legal team and a link to the original press release are provided below for those seeking more information or wishing to get involved.
Takeaway: Heightened Risk and Unanswered Questions Linger
With the company still facing the fallout from its abandoned trial, IMMP’s near-term outlook remains clouded by investor skepticism and regulatory review. For stakeholders, the key questions revolve around when—or if—greater transparency and restored confidence will return.
For more information or to participate in the investigation:
Levi & Korsinsky, LLP
33 Whitehall Street, 27th Floor
New York, NY 10004
jlevi@levikorsinsky.com
Tel: (212) 363-7500
View original press release
Contact Information:
If you have feedback or concerns about the content, please feel free to reach out to us via email at support@marketchameleon.com.
About the Publisher - Marketchameleon.com:
Marketchameleon is a comprehensive financial research and analysis website specializing in stock and options markets. We leverage extensive data, models, and analytics to provide valuable insights into these markets. Our primary goal is to assist traders in identifying potential market developments and assessing potential risks and rewards.
NOTE: Stock and option trading involves risk that may not be suitable for all investors. Examples contained within this report are simulated and may have limitations. Average returns and occurrences are calculated from snapshots of market mid-point prices and were not actually executed, so they do not reflect actual trades, fees, or execution costs. This report is for informational purposes only, and is not intended to be a recommendation to buy or sell any security. Neither Market Chameleon nor any other party makes warranties regarding results from its usage. Past performance does not guarantee future results. Please consult a financial advisor before executing any trades. You can read more about option risks and characteristics at theocc.com.
The information is provided for informational purposes only and should not be construed as investment advice. All stock price information is provided and transmitted as received from independent third-party data sources. The Information should only be used as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments and trading strategies. The Company does not guarantee the accuracy, completeness or timeliness of the Information.
Disclosure: This article was generated with the assistance of AI